@article{51acd7d2b9704aabb42578b0da1487a4,
title = "Culture-positive endophthalmitis after open globe injuries with and without retained intraocular foreign bodies",
abstract = "BACKGROUND AND OBJECTIVE: To report the visual and anatomical outcomes and microbiologic spectrum of culture-positive endophthalmitis in open globe injuries (OGIs) with or without intraocular foreign bodies (IOFBs). PATIENTS AND METHODS: A retrospective, interventional case series of OGIs (n = 718) treated between 2004 and 2015. Patients underwent a management protocol for OGI, including systemic broad-spectrum antibiotics, on presentation. RESULTS: Culture-positive cases of endophthalmitis after open globe repair occurred in 2.1% of eyes (n = 15 of 718 eyes); two eyes had evidence of endophthalmitis on presentation. The most common organism was Staphylococcus species (five of 17 eyes). An IOFB was present in 6.8% of eyes (n = 49 of 718 eyes). All of these eyes received prophylactic intravitreal antimicrobials. In eyes with IOFB, the rate of culture-positive endophthalmitis after initial globe repair was 8.1% (n = 4 of 49 eyes) versus 1.6% (n = 11 of 669 eyes) in eyes without IOFB (P < .01). CONCLUSION: Culture-positive endophthalmitis was identified after OGIs more often in eyes with a concurrent IOFB.",
author = "Banker, {Tanuj P.} and McClellan, {Andrew J.} and Wilson, {Benjamin D.} and Juan, {Fabiana M.} and Kuriyan, {Ajay E.} and Nidhi Relhan and Chen, {Felix V.} and Weichel, {Eric D.} and Albini, {Thomas A.} and Berrocal, {Audina M.} and Jay Sridhar and Gregori, {Ninel Z.} and Townsend, {Justin H.} and Flynn, {Harry W.}",
note = "Funding Information: From the Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami (TPB, AJM, BDW, FMJ, AEK, NR, FVC, TAA, AMB, JS, NZG, JHT, JWF); and the Retina Group of Washington, Washington, DC (EDW). Originally submitted December 20, 2016. Version received May 14, 2017. Accepted for publication June 2, 2017. This research is funded in part by NIH Center Core Grant P30EY014801 (Bethesda, Maryland), Research to Prevent Blindness Unrestricted Grant (New York, New York), and the Department of Defense (DOD Grant #W81XWH-09-1-0675) (Washington, DC). The sponsor or funding organization had no role in the design or conduct of this research. Dr. Gregori is a consultant to Regeneron and is supported in part by NIH Center Core Grant P30EY014801 (Bethesda, MS) and a Research to Prevent Blindness Unrestricted Grant. Drs. Flynn Jr. and Relhan are supported in part by NIH Center Core Grant P30EY014801 (Bethesda, MS) and a Research to Prevent Blindness Unrestricted Grant. The remaining authors report no relevant financial disclosures. Address correspondence to Harry W. Flynn Jr., MD, Bascom Palmer Eye Institute, 900 NW 17th St, Miami, FL 33136; email: HFlynn@med.miami.edu. doi: 10.3928/23258160-20170802-05",
year = "2017",
month = aug,
doi = "10.3928/23258160-20170802-05",
language = "English (US)",
volume = "48",
pages = "632--637",
journal = "Ophthalmic Surgery and Lasers",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "8",
}